This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

RD Legal Funding Offers Post-Settlement Advances As Johnson & Johnson Makes Settlement Offer To DePuy Litigants Following FDA Warning

However the recent FDA proposal does not address all the concerns with the devices. DePuy identified reasons for the failure of the hip replacement as component loosening, misalignment, infection, bone fracture, dislocation, metal sensitivity, and pain. Problems with the devices go beyond the risks of replacement surgeries. Additional complications may include:

  • Residual - possibly deadly - metal fragments going undetected for years;
  • Increased metal ion levels in the blood;
  • Bone staining;
  • Swelling;
  • Nerve, tissue and/or muscle damage or necrosis;
  • Damage to the central nervous system including thyroid and heart;
  • Poisoning of major organs causing genetic changes and increasing cancer risks, particularly to the kidneys and bladder.

Another factor in J & J's willingness to settle the suits may be their agreement, in September 2007, along with three other companies to pay $311 million in fines - without admitting any wrongdoing - to resolve U.S. Department of Justice allegations that they paid physicians kickbacks to use their artificial hip and knee products. The settlement agreement allowed the companies to continue to enter into product development agreements with doctors, compensating them with royalties based on future sales. DePuy paid nearly $48 million to doctors in 2009 and almost $33 million in the first 9 months of 2010.

For more information about post-settlement financing, DePuy litigants and their attorneys should contact RD Legal Funding at 1-800-565-5177 or go to Founded in 1997, RD Legal Funding is now one of the nation's leading providers of post-settlement lawsuit funding to attorneys and plaintiffs.


SOURCE RD Legal Funding

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.06 -0.19%
FB $117.29 -0.44%
GOOG $703.74 0.33%
TSLA $209.77 -0.83%
YHOO $36.98 0.11%


Chart of I:DJI
DOW 17,648.59 -12.12 -0.07%
S&P 500 2,048.45 -2.18 -0.11%
NASDAQ 4,714.6390 -2.4550 -0.05%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs